Evommune (EVMN) Accumulated Depreciation & Amortization (2024 - 2026)
Evommune (EVMN) reported Accumulated Depreciation & Amortization of $300000.0 for Q1 2026, up 50.0% year-over-year from $200000.0 in Q1 2025, and down 50.0% on a QoQ basis from $600000.0 in Q4 2025.
Evommune (EVMN) has 3 years of Accumulated Depreciation & Amortization data on file, last reported at $300000.0 in Q1 2026.
- Quarterly Accumulated Depreciation & Amortization rose 50.0% year-over-year to $300000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $300000.0 (up 50.0% YoY) and the FY2025 annual result came in at $600000.0, up 20.0% from the prior year.
- Accumulated Depreciation & Amortization slipped to $300000.0 in Q1 2026 per EVMN's latest filing, from $600000.0 in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $600000.0 in Q4 2025 and bottomed at $200000.0 in Q1 2025.
- The 3-year median for Accumulated Depreciation & Amortization is $400000.0 (2024), against an average of $400000.0.
- The widest annual swing landed in 2025, when Accumulated Depreciation & Amortization increased 20.0%; it then jumped 50.0% in 2026.
- Tracing EVMN's Accumulated Depreciation & Amortization over 3 years: stood at $500000.0 in 2024, then climbed by 20.0% to $600000.0 in 2025, then tumbled by 50.0% to $300000.0 in 2026.
- Per Business Quant, the three latest EVMN Accumulated Depreciation & Amortization figures stand at $300000.0 (Q1 2026), $600000.0 (Q4 2025), and $200000.0 (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Evommune | 744.11 Mn | 532.65 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 300,000.00 |
| Mar 31, 2026 | 300,000.00 |
| Dec 31, 2025 | 600,000.00 |
| Dec 31, 2025 | 600,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Dec 31, 2024 | 500,000.00 |
| Dec 31, 2024 | 500,000.00 |